Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 3991-4000 of 11729

Edit search filters
  1. A Study to Monitor Cardiac Amyloidosis Patients with Implantable Event Monitors

    Rochester, MN

  2. A Study Of Unesbulin In Participants With Advanced Leiomyosarcoma (LMS)

    Jacksonville, FL

  3. Open-Label Study Of The CDK4/6 Inhibitor SPH4336 In Subjects With Locally Advanced Or Metastatic Liposarcomas

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  4. A Study To Assess The Safety And Antitumor Activity Of Genetically Engineered T Cells In NY-ESO-1 And/or LAGE-1a Positive Solid Tumors

    Jacksonville, FL, Rochester, MN

  5. Study Of Lurbinectedin In Combination With Doxorubicin Versus Doxorubicin Alone As First-line Treatment In Participants With Metastatic Leiomyosarcoma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  6. Saruparib (AZD5305) Plus Camizestrant Or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy Or Plus Camizestrant In HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, Or PALB2m Advanced Breast Cancer

    Jacksonville, FL, Rochester, MN

  7. Proton SFRT V. SBRT For Borderline Unresectable/oligometastatic/recurrent Oral Cavity Cancer

    Rochester, MN

  8. A Phase 3 Efficacy And Safety Study Of Pitolisant In Patients With Prader-Willi Syndrome

    Rochester, MN

  9. A Study Of BH-30643 In Subjects With Locally Advanced Or Metastatic NSCLC Harboring EGFR And/or HER2 Mutations

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  10. A Study to Evaluate Letrozole in Patients with Hepatopulmonary Syndrome

    Rochester, MN

.

Mayo Clinic Footer